Industry
Biotechnology
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Loading...
Open
1.72
Mkt cap
66M
Volume
111K
High
1.84
P/E Ratio
-4.10
52-wk high
4.00
Low
1.60
Div yield
N/A
52-wk low
0.78
Portfolio Pulse from
November 11, 2024 | 1:15 pm
Portfolio Pulse from Benzinga Insights
October 03, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
October 01, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:16 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:44 am
Portfolio Pulse from Benzinga Newsdesk
May 03, 2024 | 11:24 am
Portfolio Pulse from Benzinga Newsdesk
April 29, 2024 | 9:35 pm
Portfolio Pulse from Benzinga Insights
March 07, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Insights
March 06, 2024 | 1:08 pm
Portfolio Pulse from Avi Kapoor
March 05, 2024 | 6:11 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.